Several antigen targets for CAR-T therapy of breast cancer have been discovered through preclinical studies, which include FRα, EGFR, AXL receptor tyrosine kinase (AXL), NKG2D, integrin αvβ3, c-Met, HER2, MUC1, mesothelin, receptor tyrosine kinase-like orphan receptor 1 (ROR1), tumor endothelial marker 8 (TEM8), trophoblast cell-surface antigen 2 (TROP2), etc. [233]. Here, ANTXR1 is linked to breast carcinoma.